Generation BioGBIO
GBIO
About: Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Employees: 115
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
1% more funds holding
Funds holding: 80 [Q4 2024] → 81 (+1) [Q1 2025]
9.44% less ownership
Funds ownership: 80.63% [Q4 2024] → 71.19% (-9.44%) [Q1 2025]
59% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 37
66% less capital invested
Capital invested by funds: $57.1M [Q4 2024] → $19.3M (-$37.8M) [Q1 2025]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
2,067%
upside
Avg. target
$8.50
2,203%
upside
High target
$9
2,338%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Needham Gil Blum | 2,067%upside $8 | Buy Reiterated | 8 May 2025 |
Canaccord Genuity Whitney Ijem | 2,338%upside $9 | Buy Maintained | 17 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D.
Negative
Zacks Investment Research
1 month ago
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $1.12 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and portfolio strategy to be announced mid-2025 - Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and first quarter 2025 financial results.
Neutral
GlobeNewsWire
2 months ago
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET.
Negative
Zacks Investment Research
3 months ago
Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.53 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases
Neutral
GlobeNewsWire
3 months ago
Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston.
Neutral
Business Wire
4 months ago
Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.
MUNICH, Germany--(BUSINESS WIRE)--Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company.
Neutral
GlobeNewsWire
5 months ago
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company working to change what is possible for people living with T cell-driven autoimmune diseases, announced it is leveraging its validated T cell-directed lipid nanoparticle (ctLNP) to develop siRNA therapeutics to silence disease-driving targets in T cells. “We are excited to move Generation Bio toward the clinic by deploying our ctLNP to deliver siRNA to T cells. By precisely modulating T cell activity in vivo we believe we can address high-value, currently undruggable targets involved in the inflammation and tissue damage associated with T cell-driven autoimmune diseases,” said Geoff McDonough, M.D., chief executive officer of Generation Bio. “Our aim is to silence therapeutic T cell targets without impacting other immune cell types, unlocking a powerful new application for siRNA in the field. We plan to submit our first IND in the second half of 2026 and to enter the clinic within our cash runway, which is into the second half of 2027.”
Negative
Zacks Investment Research
7 months ago
Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates
Generation Bio Co. (GBIO) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.43 per share a year ago.
Charts implemented using Lightweight Charts™